Clinical trial
Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00064142 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00064142 |
|---|---|
| Title | Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma |
| Official title | A Phase II Trial of Topical Halofuginone in Patients With HIV Related Kaposi's Sarcoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | AIDS-related Kaposi Sarcoma, Recurrent Kaposi Sarcoma |
| Intervention type | Drug, Other |
| Interventions | halofuginone hydrobromide, placebo, laboratory biomarker analysis, pharmacological study |
| Enrollment | 30 |
| Start date | May 1, 2003 |
| Primary completion | Dec 1, 2006 |
| First posted | Jul 9, 2003 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: